February 2023 in “International Journal of Pharmaceutics” In this study, the researchers developed minoxidil cubosomes using nanotechnology, which improved drug penetration in the skin, showed greater hair growth efficacy, and reduced adverse skin reactions compared to traditional minoxidil solutions.
39 citations
,
April 2010 in “International Journal of Pharmaceutics” This study found that using monoolein cubic phase nanoparticles with an entrapped hydroxypropyl β-cyclodextrin/minoxidil complex increased minoxidil skin permeation, but minoxidil retention in the skin was higher with a traditional solution.
25 citations
,
January 2024 in “Journal of Lipids” This review reports that cubosomes, used as drug nanocarriers in topical treatments, offer potential benefits for managing skin and eye diseases by improving bioadhesion, retention, and sustained release compared to conventional formulations, but also face manufacturing and biological challenges for effective clinical outcomes.
This study found that a data-driven model using XGBoost effectively predicts individualized responses to minoxidil for androgenetic alopecia, outperforming traditional methods in accuracy and reliability.
12 citations
,
September 2021 in “Journal of molecular structure” In this study, researchers created a new molecular salt from minoxidil and 2,4-dihydroxybenzoic acid, finding it superior to raw minoxidil for promoting hair growth in a mouse model, suggesting it may be a promising candidate for treating hair loss.